Pharmacokinetics, Safety and Tolerability of BI 1015550 Following Oral Administration in Male and Female Participants With Different Degrees of Hepatic Impairment (Child-Pugh Classification A and B) Compared With Matched Male and Female Participants With Normal Hepatic Function (an Open-label, Non-randomised, Single-dose, Parallel, Individual-matched Design Trial)
Latest Information Update: 10 Oct 2025
At a glance
- Drugs Nerandomilast (Primary)
- Indications Idiopathic pulmonary fibrosis; Interstitial lung diseases
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 22 Sep 2023 Status changed from recruiting to completed.
- 04 Sep 2023 Planned End Date changed from 5 Sep 2023 to 12 Sep 2023.
- 04 Sep 2023 Planned primary completion date changed from 5 Sep 2023 to 12 Sep 2023.